BlackThorn Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BlackThorn Therapeutics, Inc.
Neumora’s once-daily oral kappa opioid receptor (KOR) antagonist navacaprant succeeded in a Phase II trial and will move into the first of three Phase III studies soon, with a US filing targeted for 2025.
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.
- Artificial Intelligence
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Neumora Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.